When was GeneScience Pharmaceuticals founded?

GeneScience Pharmaceuticals was founded in 1996 and raised its 1st funding round 25 years after it was founded.

Where is GeneScience Pharmaceuticals located?

GeneScience Pharmaceuticals is headquartered in Changchun, China.

Who is the current CEO of GeneScience Pharmaceuticals?

Lei Jin of GeneScience Pharmaceuticals.

How many employees does GeneScience Pharmaceuticals have?

As of May 31, 2026, the latest employee count at GeneScience Pharmaceuticals is 8.

Is GeneScience Pharmaceuticals a funded company?

GeneScience Pharmaceuticals is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 04, 2021.

When was the latest funding round of GeneScience Pharmaceuticals?

GeneScience Pharmaceuticals' latest funding was a $***** Series B round on Mar 04, 2021, with participation from 3 investors. Its primary sector is Genomics. In China, the Genomics sector has seen $88.5M in funding in 2026 to date.

Where does GeneScience Pharmaceuticals rank among its competitors?

GeneScience Pharmaceuticals ranks 12th amongst 66 active competitors, of which 20 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of GeneScience Pharmaceuticals?

GeneScience Pharmaceuticals' top competitors include Senti Bio, CRISPR Therapeutics and Geninus. Among them, Senti Bio secured the most recent funding round in May, 2026.

GeneScience Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provides genetically engineered pharmaceutical products. They use the technology of genetic engineering and recombinant technology to produce their several propriety like GenLei Jintropin (human growth hormone), Genfulin (rDNA origin), recombinant human granulocyte-macrophage stimulating factor gel for burn treatment, and octreotide acetate for child growth.

Website: www.gensci-china.com
Email ID: *****@gensci-china.com
Phone Number: +86 **********

Key Metrics

Founded Year

1996

Location

Changchun, China

Stage

Series B

Latest Funding Round

Series B, Mar 04, 2021, $*****

Investors

New Alliance Capital & 4 more

Ranked

12^th among 66 active competitors

Employee Count

8 as on May 31, 2026

Investment & Acquisitions

Rani Therapeutics

Similar Companies

Senti Bio & 81 more

View GeneScience Pharmaceuticals' full profile

GeneScience Pharmaceuticals has raised funding over 2 rounds. Its first funding round was on Mar 04, 2021. Its latest funding round was a Series B round on Mar 04, 2021 for $*****. 3 investors participated in its latest round. GeneScience Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of GeneScience Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2021	8116057	Series B	2899168	7244376	7812051	5762759
Mar 04, 2021	5295789	Series A	8157214	8084562	IDG Capital & 1 more	9743307

Access funding benchmarks and valuations. Sign up today!

View details of GeneScience Pharmaceuticals's funding rounds and investors

GeneScience Pharmaceuticals' employee count trend

GeneScience Pharmaceuticals has 8 employees as of May 26. Here is GeneScience Pharmaceuticals's employee count trend over the years:

Employee count trend for GeneScience Pharmaceuticals

Uncover GeneScience Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GeneScience Pharmaceuticals include Senti Bio, CRISPR Therapeutics and Geninus. Here is the list of Top 10 competitors of GeneScience Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, Franklin Templeton Investments & 10 others	63/100
3rd	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
4th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Fidelity Investments, Longitude Capital & 12 others	60/100
5th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	HBM Healthcare Investments, T. Rowe Price ... & 17 others	58/100
6th	Logomix 2019, San Carlos (United States), Series A	Provider of genome engineering platform to create artificial cells	$22.6M	Sumitomo Mitsui Banking Corporation, Globis Capital Partners ... & 15 others	57/100
7th	OXGENE 2011, Oxford (United Kingdom), Acquired	Provider of a platform for mammalian cell engineering	$28.1M	Mercia, Invesco & 6 others	57/100
8th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
9th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	55/100
10th	Avectas 2011, Dublin (Ireland), Series C	Provider of non-viral cell engineering technology platform for drug discovery	$33.5M	EIC Fund, Europa & 1 others	54/100
12th	GeneScience Pharmaceuticals 1996, Changchun (China), Series B	Provides genetically engineered pharmaceuticals products	-	Haitong Bank, IDG Capital & 3 others	51/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on GeneScience Pharmaceuticals's competitors? Click here to see the top ones

GeneScience Pharmaceuticals has a total of 1 investment in Rani Therapeutics. GeneScience Pharmaceuticals has not made any acquisitions as of now.

Here is the latest report on GeneScience Pharmaceuticals's sector:

Free

Internet of Things - Sector Report

Edition: May, 2026 (83 Pages)

View all reports related to GeneScience Pharmaceuticals

Media has covered GeneScience Pharmaceuticals for a total of 3 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.